IL311711A - Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors - Google Patents
Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitorsInfo
- Publication number
- IL311711A IL311711A IL311711A IL31171124A IL311711A IL 311711 A IL311711 A IL 311711A IL 311711 A IL311711 A IL 311711A IL 31171124 A IL31171124 A IL 31171124A IL 311711 A IL311711 A IL 311711A
- Authority
- IL
- Israel
- Prior art keywords
- arhgef12
- glaucoma
- inhibitors
- treatment
- guanine nucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163250492P | 2021-09-30 | 2021-09-30 | |
| PCT/US2022/077176 WO2023056295A1 (en) | 2021-09-30 | 2022-09-28 | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311711A true IL311711A (en) | 2024-05-01 |
Family
ID=83996920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311711A IL311711A (en) | 2021-09-30 | 2022-09-28 | Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12577562B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408535A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024535110A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099232A9 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118891050A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022357497A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232251A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311711A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023056295A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004045644A1 (ja) | 2002-11-18 | 2004-06-03 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
| WO2006104751A2 (en) * | 2005-03-30 | 2006-10-05 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
| AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| GB201107176D0 (en) * | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
| JP2022508715A (ja) | 2018-10-15 | 2022-01-19 | オキュフィア・ファーマ・インコーポレイテッド | 緑内障および関連状態の処置のための方法および組成物 |
| CA3126476A1 (en) * | 2019-01-23 | 2020-07-30 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
-
2022
- 2022-09-28 KR KR1020247014295A patent/KR20240099232A9/ko active Pending
- 2022-09-28 AU AU2022357497A patent/AU2022357497A1/en active Pending
- 2022-09-28 CA CA3232251A patent/CA3232251A1/en active Pending
- 2022-09-28 CN CN202280075189.3A patent/CN118891050A/zh active Pending
- 2022-09-28 WO PCT/US2022/077176 patent/WO2023056295A1/en not_active Ceased
- 2022-09-28 IL IL311711A patent/IL311711A/en unknown
- 2022-09-28 US US17/936,244 patent/US12577562B2/en active Active
- 2022-09-28 EP EP22797214.8A patent/EP4408535A1/en active Pending
- 2022-09-28 JP JP2024519586A patent/JP2024535110A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118891050A (zh) | 2024-11-01 |
| AU2022357497A1 (en) | 2024-04-04 |
| US12577562B2 (en) | 2026-03-17 |
| KR20240099232A9 (ko) | 2025-12-10 |
| CA3232251A1 (en) | 2023-04-06 |
| JP2024535110A (ja) | 2024-09-26 |
| WO2023056295A1 (en) | 2023-04-06 |
| US20230099109A1 (en) | 2023-03-30 |
| EP4408535A1 (en) | 2024-08-07 |
| KR20240099232A (ko) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP1742743S (ja) | 基板処理チャンバのための回転防止プロセスキット用バッフル | |
| PE20180279A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| ZA202503575B (en) | Novel prmt5 inhibitor and use thereof | |
| MX2023002324A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| DE60036540D1 (de) | Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose | |
| WO2013040528A1 (en) | Antimicrobial compounds | |
| MX2017010230A (es) | Derivados de mono- y poliazanaftaleno sustituidos y su uso. | |
| PL2250172T3 (pl) | Pirolopirazynowe inhibitory kinazy | |
| EP2234618A4 (en) | BENZOPYRANE AND ANALOGUE AS RHO KINASE INHIBITORS | |
| MX2009006756A (es) | Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv. | |
| EA201000848A1 (ru) | Ингибиторы протеинкиназы и их применение | |
| CY1116043T1 (el) | Κρυσταλλικες μορφες υδροχλωρικου αλατος (4α-r,9α-s)-1-(1η-βενζοϊμιδαζολο-5-καρβονυλ)2,3,4,4α,9,9α-εξαϋδρο-1η-ινδενο[2,1-β]πυριδινο-6-καρβονιτριλιου και χρηση τους ως αναστολεις της hsd 1 | |
| HK40113128A (en) | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors | |
| KR20240099232A9 (ko) | Rho 구아닌 뉴클레오타이드 교환 인자 12[Rho Guanine Nucleotide Exchange Factor 12, ARHGEF12] 억제제를 이용한 녹내장 치료 | |
| Wang et al. | Synthesis, SAR study and biological evaluation of novel pyrazolo [1, 5-a] pyrimidin-7-yl phenyl amides as anti-proliferative agents | |
| Tunçbilek et al. | Synthesis and antimicrobial evaluation of some new substituted purine derivatives | |
| MX2010005787A (es) | Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina. | |
| HK1212212A1 (en) | Compositions and methods for inhibiting activity of hypoxia-inducible transcription factor complex and its use for treatment of tumors | |
| MX2026000476A (es) | Sales clorhidrato cristalinas micronizadas de compuestos inhibidores antiviricos de la helicasa-primasa | |
| CU20250003A7 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CL2025003529A1 (es) | Nuevos polimorfos de (s)-6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida en forma cristalina. | |
| BRPI0508927A (pt) | compostos úteis para o tratamento de doenças | |
| WO2023230478A3 (en) | Treatment of sos2 related diseases and disorders | |
| TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents | |
| EA201992341A8 (ru) | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |